Sigida duo drops Ch. 10ml vial

$8.18

Sigida duo drops Ch. 10ml vial

Quantity:

Description

Composition
Active substance:
1 ml of the preparation contains:
Diphenhydramine hydrochloride 1.0 mg; Naphazoline nitrate (Naphthyzinum) 0.33 mg.
Excipients:
Boric acid 16.0 mg, 1.125 mg of Macrogol 300, 1.0 mg of Sodium hyaluronate, Disodium edetate dihydrate (Trilon B) 0.5 mg, 1 M sodium hydroxide solution or nitric acid 0.1 M solution until pH 4,0 – 7.0
Water for injections to 1 mL.
Description:
Clear, colorless or slightly colored liquid.
Product form:
Eye drops 0.1% + 0.033%.
10 ml vial
Contraindications
-giperchuvstvitelnost to any component of the product (including to sympathomimetic amines); – pregnancy; – breast-feeding; – closure glaucoma; – Children’s age (up to 2 years).
Carefully:
Should not be used in the event of a prolonged drop conjunctivitis, they can be applied for a short time during exacerbation of chronic disease. Systemic action components of the drug after insertion into the conjunctival sac are unlikely, but it should be used with caution in patients with hypertension, arrhythmia; atherosclerosis, chronic rhinitis, bronchial asthma, hypersensitivity to sympathomimetic amines, hyperthyroidism, as well as in benign prostatic hyperplasia, and in the elderly. These patients should be warned that in case of occurrence of any systemic reactions, indicating the absorption of naphazoline, you must stop using the product. Do not use the drug in infants and children up to 6 years of age because of the possible occurrence of potentially dangerous side effects. Patients should be warned that the persistence of symptoms of irritation or pain in the eyes for more than 72 hours is an indication to remove the drug. Not use this drug more than 5 days or at intervals of less than 3 hours because of the risk of development syndrome leading to edema and secondary strengthening hypersecretion and possible development of persistent epithelial changes.
Dosage
1 mg + 0.33 mg / ml
Indications
-obostrenie seasonal or perennial allergic conjunctivitis; – inflammatory conditions associated with conjunctival irritation as a result of contact lenses, sunlight, cigarette smoke, contact with water in the swimming pool, and others.
Interaction with other drugs
Use of a preparation containing naphazoline, simultaneously with the reception of tricyclic antidepressants can potentiate naphazoline vasoconstrictive action.
Simultaneous application naphazoline with inhibitors of monoamine oxidase can result in the development of hypertensive crisis.
Overdose
Symptoms: prolonged or too frequent use in children under 6 years of age can lead to lethargy CNS, hypothermia (low body temperature), long-term mydriasis, increased blood pressure, tachycardia, coma. Treatment: symptomatic.
pharmachologic effect
Pharmacological group:
Antiallergic agent combination (H1-histamine receptor blocker + alpha-agonists).
Pharmacodynamics:
A combined preparation having antihistamine (diphenhydramine) and vasoconstrictor (naphazoline) effect. Diphenhydramine is an antagonist of histamine H1-receptors. By competitive blockade of histamine H1-receptor it reduces allergic symptoms, especially those associated with the release of histamine, such as increased permeability and vasodilation. Naphazoline stimulates alpha-adrenergic receptors of vascular, its local application leads to a narrowing of the blood vessels and reduce the symptoms of an inflammatory condition.
Pharmacokinetics:
Full naphazoline local effect is already apparent after 5 minutes from the time of application. The action lasts 6-8 hours. Naphazoline can be absorbed by the mucous membranes, causing systemic effects, although such action is in adults after administration into the conjunctival sac it is unlikely. Systemic reactions occur mainly in elderly patients and in young children.
systemic manifestation of diphenhydramine unlikely.
Pregnancy and breast-feeding
In the use of the drug is not recommended during pregnancy. If necessary, use during lactation should stop breastfeeding.
Conditions of supply of pharmacies
Prescription.
side effects
Burning, itching, redness, conjunctival irritation, eye pain, visual disturbances, dry nasal mucosa, mydriasis, increased intraocular pressure.
It described an isolated case corneal opacity (using for 7 days at least 10 times a day), which disappeared after stopping treatment. Long-term use can lead to local changes of the epithelium associated with hypoxia (worse prognosis).
special instructions
The drug is intended for topical use: instillation into the conjunctival sac.
Effects on ability to drive vehicles and mechanisms:
Because of the potential visual disturbances should be used with caution in patients who drives the vehicle and serving mechanisms.
Storage conditions
Store at a temperature not higher than 25 C. Keep out of reach of children.
Dosing and Administration
Topically in the conjunctival sac.
Adults and children over 6 years: 1-2 drops into the conjunctival sac as needed every 6-8 hours. The drug should not be used longer than 3-5 days.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg
Manufacturer

Grotex Ltd.

There are no reviews yet.

Add your review